Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogenic human liver stem cell therapy - Unicyte AG

Drug Profile

Allogenic human liver stem cell therapy - Unicyte AG

Alternative Names: Allogeneic adult liver-derived stem cells; Allogeneic human adult liver-derived stem cells; HLSC-001

Latest Information Update: 03 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unicyte AG
  • Class Hepatoprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inborn urea cycle disorders; Ornithine carbamoyltransferase deficiency disease; Inborn error metabolic disorders
  • New Molecular Entity No

Highest Development Phases

  • Phase II Inborn urea cycle disorders

Most Recent Events

  • 19 Sep 2022 Phase-II clinical trials in Inborn urea cycle disorders (In infants, In children, In neonates) in France (Intrahepatic) (EudraCT2022-000933-18; 700356871)
  • 05 Mar 2012 Allogenic human liver stem cells - Unicyte AG receives Orphan Drug status for Inborn urea cycle disorders, Ornithine carbamoyltransferase deficiency disease and Inborn error metabolic disorders in European Union (EMA website, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top